key: cord-0692598-xva26eit authors: Bronstein, Yotam; Adler, Amos; Katash, Haytham; Halutz, Ora; Herishanu, Yair; Levytskyi, Katia title: Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID‐19 infection date: 2021-11-13 journal: J Med Virol DOI: 10.1002/jmv.27445 sha: 8c0dc695d041501245a06000a3a201d69795e682 doc_id: 692598 cord_uid: xva26eit Immunocompromised patients have an increased risk of persistent COVID‐19 disease. We report here the clinical course of two patients with hematologic malignancies hospitalized due to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. In both patients, viral evolution including new spike gene mutations that occurred following treatment with anti‐SARS‐CoV‐2 antibodies preparations, including convalescent plasma and bamlanivimab. These cases demonstrate the possibility of antibody‐resistant SARS‐CoV‐2 infections evolution in immunocompromised patients. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has spread worldwide since late 2019, causing a massive burden of morbidity and mortality. Immunocompromised patients, particularly those with hematologic malignancies 1 have an increased risk of severe disease and higher rates of intensive care admissions and mortality. While most adults with COVID-19 infection remain infectious up to 10 days after symptoms onset, there are several reports that immunocompromised adults might remain infectious for 3 weeks and even more. 2, 3 Furthermore, recent studies 4 show that chronic infection may lead to SARS-CoV-2 viral mutations, especially in patients treated with convalescent plasma and monoclonal antibody therapy. In this study, we report the clinical course of two patients with hematologic malignancies who were hospitalized due to SARS-CoV-2 infection. We describe the viral evolution during their hospital course in relation to their treatment with various SARS-CoV-2 antibody preparations ( Figure 1 ). The study was conducted at the Tel Aviv Sourasky Medical Center (TASMC), a 1400-bed tertiary center. Medical and laboratory data were obtained from the patient's electronic health record. The study was approved by the Ethics committee of the Tel Aviv Sourasky Medical Center. (3) the Xpert ® Xpress SARS-CoV-2, targeting the E and the N genes; (4) the Simplexa™ COVID-19 Direct assay, targeting the S and the ORF genes. Ten days following the diagnosis, the patient was admitted to TASMC due to bilateral pneumonia and was treated with ceftriaxone, levofloxacin, and bamlanivimab. Although his respiratory symptoms improved, the patient had persistent fever and positive COVID-19 tests on Day 12 of his admission. Hence, treatment with dexamethasone was initiated followed by COVID-19 convalescent plasma. On Day 21 of his admission, the patient was given a course of intravenous immunoglobulin treatment due to persistent fever. No other source for his symptoms besides COVID-19 was identified despite extensive evaluation and hence the second course of COVID-19 convalescent plasma was administered. On Day 37 of his admission, he started a course of remdesivir for 5 days, which was followed by resolution of the fever and an improvement of his general condition. The patient was discharged on Day 43 of his admission while con- diagnosed with HL 4 months before his admission that was complicated by pleural and pericardial effusion and a right cardiac ventricle thrombus. He was treated with anticoagulants but refused chemotherapy. Five days before his admission, the patient was tested positive by COVID-19 PCR and was admitted later due to worsening dyspnea. On admission, the patient and was found to have recurrent bilateral pleural effusions, a pleural embolism, and an inferior vena cava obstruction. Hence, it was unclear whether his symptoms were due to SARS-CoV-2 infection or due to his underlying illness. The patient was initially treated with high-flow oxygen, pleurocentesis, and dexamethasone. On the 15th day of his admission and due to persistence of positive COVID-19 PCR, the patient received bamlanivimab. The patient's condition continued to deteriorate and 1 month after his admission he agreed to chemotherapy with dacarbazine, doxorubicin, and vincristine and showed improvement. In the following 2 months, the patient was hospitalized twice due to fever. COVID-19 PCR was persistently positive throughout that period. The spike gene mutations, the total number of mutations (compared with the wild-type strain MN908947), as well as the PCR C t values, are presented in Tables 1 and 2 . The authors declare that there are no conflict of interests. The data that support the findings of this study are available from the corresponding author upon reasonable request. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer SARS-CoV-2 evolution during treatment of chronic infection A new coronavirus associated with human respiratory disease in China Acquisition and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient. medRxiv Bamlanivimab treatment leads to rapid selection of immune escape variant carrying E484K mutation in a B.1.1.7 infected and immunosuppressed patient Emergence of SARS-CoV-2 resistance with monoclonal antibody therapy. medRxiv Emergence of E484K mutation following bamlanivimab monotherapy among highrisk patients infected with the alpha variant of SARS-CoV-2 SARS-CoV-2 variants in immunocompromised patient given antibody monotherapy A SARS-CoV-2 variant with L452R and E484Q neutralization resistance mutations Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants Neutralizing monoclonal antibodies for treatment of COVID-19 Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity The rise and fall of an emerging SARS-CoV-2 variant with the spike protein mutation L452R Emergence of SARS-COV-2 spike protein escape mutation Q493R after treatment for COVID-19 Emergence of Q493R mutation in SARS-CoV-2 spike protein during bamlanivimab/etesevimab treatment and resistance to viral clearance